Vancomycin dosing and monitoring 2 years after the guidelines

References

• Rybak M, Lomaestro B, Rotschafer JC et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am. J. Health Syst. Pharm.66(1), 82–98 (2009).
   PubMedGoogle Scholar
• Liu C, Bayer A, Cosgrove SE et al. Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin. Infect. Dis.52, e18–e55 (2011).
   PubMed Web of Science ®Google Scholar
• Gould IM, Cauda R, Esposito S et al. Management of serious methicillin-resistant Staphylococcus aureus infections: what are the limits? Int. J. Antimicrob Agents37, 202–209 (2011).
   PubMed Web of Science ®Google Scholar
• Kanh AR, Kahn S, Zimmerman V, Baddour LM, Tieyjeh IM. Quality and strength of evidence of the Infectious Diseases Society of America Clinical Practice Guidelines. Clin. Infect. Dis.51(10), 1147–1156 (2010).
   PubMed Web of Science ®Google Scholar
• Deresinski S. Guiding clinical care through evidence-free zones. Editorial commentary. Clin. Infect. Dis.51(10), 1157–1159 (2010).
   PubMed Web of Science ®Google Scholar
• Guyatt G, Akl EA, Hirsh J et al. The vexing problem of guidelines and conflict of interest: a potential solution. Ann. Intern. Med.152, 738–741 (2010).
   PubMed Web of Science ®Google Scholar
• Wang G, Hindler JF, Ward KW, Bruckner DA. Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J. Clin. Microbiol.44(11), 3883–3886 (2006).
   PubMed Web of Science ®Google Scholar
• Chua K, Howden BP. Treating Gram-positive infections: vancomycin update and the whys, wherefores and evidence base for continuous infusion of anti-Gram-positive-antibiotics. Curr. Opin. Infect. Dis.22, 525–534 (2009).
   PubMed Web of Science ®Google Scholar
• Leonard SN, Rossi KL, Newton KL, Rybak MJ. Evaluation of the Etest GRD for the detection of Staphylococcus aureus with reduced susceptibility to glycopeptides. J. Antimicrob. Chemother.63, 489–492 (2009).
   PubMed Web of Science ®Google Scholar
• Sader HS, Rhomberg PR, Jones RN. Nine-hospital study comparing broth microdilution and Etest method results for vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother.53, 3162–3165 (2009).
   PubMed Web of Science ®Google Scholar
• Prakash V, Lewis JS 2nd, Jorgensen JH. Vancomycin MICs with methicillin-resistant Staphylococcus aureus (MRSA) isolates differ based upon the susceptibility test method used. Antimicrob. Agents Chemother.52(12), 4528 (2008).
   PubMed Web of Science ®Google Scholar
• Hidayat LK, Hsu DI, Quist K, Shriner A, Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch. Intern. Med.166, 2138–2144 (2006).
   PubMed Web of Science ®Google Scholar
• Lodise TP, Graves J, Evans A et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob. Agents Chemother.52(9), 3315–3320 (2008).
   PubMed Web of Science ®Google Scholar
• Haque NZ, Zuniga LC, Peyrani P et al. Relationship of vancomycin minimum inhibitory concentration to mortality in patients with methicillin-resistant Staphylococcus aureus hospital-acquired, ventilatory-associated, or health-care associated pneumonia. Chest238(6), 1356–1362 (2010).
   Google Scholar
• Price J, Atkinson S, Llewelyn M, Paul J. Paradoxical relationship between clinical outcome of Staphylococcus aureus bacteremia and minimum inhibitory concentration of vancomycin. Clin. Infect. Dis.48, 997–998 (2009).
   PubMed Web of Science ®Google Scholar
• Peleg AY, Monga D, Pillai S, Mylonakis E, Moellering RC, Eliopoulos G. Reduced susceptibility to vancomycin influences pathogenicity in Staphylococcus aureus infection. J. Infect. Dis.199, 532–536 (2009).
   PubMed Web of Science ®Google Scholar
• Lalueza A, Chaves F, San Juan R, Daskalaki M, Otero JR, Aguado JM. Is high vancomycin minimum inhibitory concentration a good marker to predict the outcome of methicillin-resistant Staphylococcus aureus bacteremia? J. Infect. Dis.201, 311–313 (2010).
   PubMed Web of Science ®Google Scholar
• Soriano A, Marco F, Martinez JA et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin. Infect. Dis.46, 193–200 (2008).
   PubMed Web of Science ®Google Scholar
• Leonard SN, Rybak MJ. Evaluation of vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus and heterogeneously vancomycin-intermediate S. aureus in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations. J. Antimicrob. Chemother.63, 155–160 (2009).
   PubMed Web of Science ®Google Scholar
• Moise-Broder PA, Sakoulas G, Eliopoulos GM, Schentag JJ, Forrest A, Moellering RC. Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin failure. Clin. Infect. Dis.38, 1700–1705 (2004).
   PubMed Web of Science ®Google Scholar
• Tsuji BT, Harigaya Y, Lesse AJ, Sakoulas G, Mylotte JM. Loss of vancomycin bactericidal activity against accessory gene regulator (agr) dysfunctional Staphylococcus aureus under conditions of high bacterial density. Diag. Microbiol. Infect. Dis.64, 220–224 (2009).
   PubMed Web of Science ®Google Scholar
• Howden BP, Davies JK, Johnson PDR, Stinear TP, Grayson ML. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin. Microbiol. Rev.23(1), 99–139 (2010).
   PubMed Web of Science ®Google Scholar
• Yang Y, McBride MV, Rodvold KA et al. Hospital policies and practices on prevention and treatment of infections caused by methicillin-resistant Staphylococcus aureus. Am. J. Health Syst. Pharm.67, 1017–1024 (2010).
   PubMed Web of Science ®Google Scholar
• Craig WA, Andes DR. In vivo pharmacodynamics of vancomycin against VISA, heteroresistant VISA (hVISA) and VSSA in the neutropenic murine thigh-infection model. Programs and Abstracts of the 46th Interscience Congress of Antimicrobial Agents and Chemotherapy (ICAAC). San Francisco, CA, USA (2006) (Abstract A-644).
   Google Scholar
• Craig WA. Basic pharmacodynamics of antibacterials with clinical applications to the use of β-lactams, glycopeptides and linezolid. Infect. Dis. Clin. N. Am.17, 479–501 (2003).
   PubMed Web of Science ®Google Scholar
• Ebert S. In vivo cidal activity and pharmacokinetic parameters for vancomycin against methicillin-susceptible and -resistant S. aureus. Programs and Abstracts of the 27th Interscience Congress of Antimicrobial Agents and Chemotherapy (ICAAC). New York, NY , USA (1987) (Abstract 439).
   Google Scholar
• Moise-Broder PA, Forrest A, Birmingham MC, Schentag J. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin. Pharmacokinet.43(13), 925–942 (2004).
   PubMed Web of Science ®Google Scholar
• Dehority W. Use of vancomycin in pediatrics. Ped. Infect. Dis. J.29(5), 462–464 (2010).
   PubMed Web of Science ®Google Scholar
• DeRyke CA, Alexander DP. Optimizing vancomycin dosing through pharmacodynamic assessment targeting area under the concentration-time curve/minimum inhibitory concentration. Hosp. Pharm.44(9), 751–765 (2009).
   Google Scholar
• Drusano GL, Rubino CM, Ambrose PG et al. Penetration of vancomycin (V) into epithelial lining fluid (ELF). Programs and Abstracts of the 47th Interscience Congress of Antimicrobial Agents and Chemotherapy (ICAAC). Chicago, IL, USA (2007) (Abstract A-11).
   Google Scholar
• Harigaya Y, Bulitta JB, Forrest A et al. Pharmacodynamics of vancomycin at simulated epithelial lining fluid concentrations against methicillin-resistant Staphylococcus aureus (MRSA): implications for dosing in MRSA pneumonia. Antimicrob. Agents Chemother.53(9), 3894–3901 (2009).
   PubMed Web of Science ®Google Scholar
• American Thoracic society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am. J. Resp. Crit. Care Med.171, 388–416 (2005).
   PubMed Web of Science ®Google Scholar
• Stryjewski ME, Graham DR, Wilson SE et al. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by Gram-positive organisms. Clin. Infect. Dis.46, 1683–1693 (2008).
   PubMed Web of Science ®Google Scholar
• Kettle JK, Grace JW, Schaefer S, Desai A. Treatment of methicillin-resistant Staphylococcus aureus with a vancomycin minimum inhibitory concentration of 2 mcg/ml. Hosp. Pharm.45(5), 375–380 (2010).
   Google Scholar
• Deresinski S. Vancomycin in combination with other antibiotics for the treatment of serious methicillin-resistant Staphylococcus aureus infections. Clin. Infect. Dis.49, 1072–1079 (2009).
   PubMed Web of Science ®Google Scholar
• Han PY, Dufful SB, Kirkpatrick CMJ, Green B. Dosing in obesity: a simple solution to a big problem. Clin. Pharmacol. Therapeut.82(5), 505–508 (2007).
   PubMed Web of Science ®Google Scholar
• Barraclough K, Harris M, Montessori V, Levin A. An unusual case of acute kidney injury due to vancomycin – lessons learnt from reliance on eGFR. Nephrol. Dial. Transplant.22, 2391–2394 (2007).
   PubMed Web of Science ®Google Scholar
• Young JF, Luecke RH, Pearce BA et al. Human organ/tissue growth algorithms that include obese individuals and black/white population organ weight similarities from autopsy data. J. Toxicol. Environ. Health. Part A72, 527–540 (2009).
   PubMed Web of Science ®Google Scholar
• Pai M. Estimating the glomerular filtration rate in obese adult patients for drug dosing. Adv. Chron. Kid. Dis.17(5), e53–e62 (2010).
   PubMedGoogle Scholar
• Vandecasteele SJ, De Vriese AS. Recent changes in vancomycin use in renal failure. Kidney Int.77, 760–764 (2010).
   PubMed Web of Science ®Google Scholar
• Frymoyer A, Hersh AL, Benet LZ, Guglielmo BJ. Current recommended dosing of vancomycin for children with invasive methicillin-resistant Staphylococcus aureus infections is inadequate. Ped. Infect. Dis. J.28(5), 398–402 (2009).
   PubMed Web of Science ®Google Scholar
• Elligsen M, Walker SAN, Walker SE, Simor A. Optimizing initial vancomycin dosing in burn patients. Burns37(3), 406–414 (2010).
   PubMed Web of Science ®Google Scholar
• Revilla N, Martin-Suarez A, Perez MP, Gonzalez FM, del Mar Fernandez de Gatta M. Vancomycin dosing assessment in intensive care unit patients based on a population pharmacokinetic/pharmacodynamic simulation. Br. J. Clin. Pharmacol.70(2), 201–212 (2010).
   PubMed Web of Science ®Google Scholar
• Wysocki M, Delatour F, Faurisson F et al. Continuous versus intermittent infusion of vancomycin in severe staphylococcal infections: prospective multicenter randomized study. Antimicrob. Agents Chemother.45(9), 2460–2467 (2001).
   PubMed Web of Science ®Google Scholar
• Ingram PAR, Lye DC, Fisher DA, Goh WP, Tam VH. Nephrotoxicity of continuous versus intermittent infusion of vancomycin in outpatient parenteral antimicrobial therapy. Int. J. Antimicrob. Agents34(6), 570–574, (2009).
   PubMed Web of Science ®Google Scholar
• Jeurissen A, Sluyts I, Rutsaert R. A higher dose of vancomycin in continuous infusion is needed in critically ill patients. Int. J. Antimicrob. Agents37(1), 75–77 (2010).
   PubMed Web of Science ®Google Scholar
• Ingram PR, Lye DC, Tambyah PA et al. Risk factors for nephrotoxicity associated with continuous vancomycin infusion in outpatient parenteral antibiotic therapy. J. Antimicrob. Chemother.62, 168–171 (2008).
   PubMed Web of Science ®Google Scholar
• Pea F, Furlanut M, Negri C et al. Prospectively validated dosing nomograms for maximizing pharmacodynamics of vancomycin administered by continuous infusion in critically ill patients. Antimicrob. Agents Chemother.53(5), 1863–1867 (2009).
   PubMed Web of Science ®Google Scholar
• Pea F, Viale P. Should the currently recommended twice-daily dosing still be considered the most appropriate regimen for treating MRSA ventilator-associated pneumonia with vancomycin? Clin. Pharmacokinet.47(3), 147–152 (2008).
   PubMed Web of Science ®Google Scholar
• Hutschala D, Kinstner C, Skhirdladze K, Thalhammer F, Muller M, Tschernko E. Influence of vancomycin on renal function in critically ill patients after cardiac surgery. Antesthesiol.111(2), 356–365 (2009).
   PubMed Web of Science ®Google Scholar
• Rybak MJ, Lomaestro B, Rotschafer J, Moellering RC, Levine DP. Reply to Panday and Sturkenboom. Clin. Infect. Dis.49, 1965 (2009).
   Web of Science ®Google Scholar
• Panday PN, Sturkenboom M. Continuous infusion of vancomycin less effective and safe than intermittent infusion, based on pharmacodynamic and pharmacokinetic principles. Clin. Infect. Dis.49, 1964–1965 (2009).
   PubMed Web of Science ®Google Scholar
• Ahmida MHS. Protective role of curcumin in nephrotoxic oxidative damage induced by vancomycin in rats. Exp. Toxicol. Pathol. DOI:10.1016/j.etp.2010.07.010 (2010) (Epub ahead of print).
   PubMedGoogle Scholar
• Dieterich C, Puey A, Lyn S et al. Gene expression analysis reveals new possible mechanisms of vancomycin-induced nephrotoxicity and identifies gene markers candidates. Toxicol. Sci.107(1), 258–269 (2009).
   PubMed Web of Science ®Google Scholar
• Mehta RL, Kellum JA, Shah SV et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care11(2), R31 (2007).
   PubMed Web of Science ®Google Scholar
• Kellum JA, Mehta RL, Angus DC, Palevsky P, Ronco C. The first international consensus conference on continuous renal replacement therapy. Kidney Int.62, 1855–1863, (2002).
   PubMed Web of Science ®Google Scholar
• Goodsaid FM, Blank M, Dieterle R et al. Novel biomarkers of acute kidney toxicity. Nature86(5), 490–496 (2009).
   Google Scholar
• Hazlewood KA, Brouse SD, Pitcher WD, Hall RG. Vancomycin-associated nephrotoxicity: grave concern or death by character assassination? Am. J. Med.123(2), 182; e1–e7 (2010).
   PubMed Web of Science ®Google Scholar
• Jeffres MN, Isakow W, Doherty JA et al. A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia. Clin. Ther.29(6), 1107–1115 (2007).
   PubMed Web of Science ®Google Scholar
• Lodise TP, Lomaestro B, Graves J, Drusano GL. Large vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob. Agents Chemother.52(4), 1330–1336 (2008).
   PubMed Web of Science ®Google Scholar
• Kunkel M, Chastre JE, Kolleff M et al. Linezolid vs vancomycin in the treatment of nosocomial pneumonia proven due to methicillin-resistant Staphylococcus aureus. Programs and Abstracts of the IDSA 48th Annual Meeting. Vancouver Canada (2010) (Abstract LB49).
   Google Scholar
• Lodise TP, Patel N, Lomaestro BM, Rodvold KA, Drusano GL. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin. Infect. Dis.49, 507–514 (2009).
   PubMed Web of Science ®Google Scholar
• Ladino M, Alex M, Mattiazzi A, Sadhu S, Schulman IH. Acute reversible vancomycin nephrotoxicity: case reports. J. Nephrol. Renal Transplant.1(1), 4–10 (2008).
   Google Scholar
• Wong-Beringer A, Joo J, Tse E, Beringer P. Vancomycin-associated nephrotoxicity: a critical appraisal of risk with high-dose therapy. Int. J. Antimicrob. Agents37(2), 95–101 (2010).
   PubMed Web of Science ®Google Scholar
• McKamy S, Hernandez E, Jahng M, Moriwaki T, Deveikis A, Le J. Incidence of risk factors influencing the development of vancomycin nephrotoxicity in children. J. Pediatr.158(3), 422–426 (2010).
   Web of Science ®Google Scholar
• Forouzesh A, Moise PA, Sakoulas G. Vancomycin ototoxicity: a reevaluation in an era of increased doses. Antimicrob. Agents Chemother.53(2), 483–486 (2009).
   PubMed Web of Science ®Google Scholar
• Shields RK, Martello JL, Potoski BA. Is vancomycin ototoxicity a significant risk? Antimicrob. Agents Chemother.53(10), 4572–4573 (2009).
   PubMedGoogle Scholar
• Vesga O, Agudelo M, Salazar BE, Rodriguez CA, Zuluaga AF. Generic vancomycin products fail in vivo despite being pharmaceutical equivalents of the innovator. Antimicrob. Agents Chemother.54(5), 3271–3279 (2010).
   PubMed Web of Science ®Google Scholar
• Fujimura S, Watanabe A, Fuse K, Kikuchi T, Bomi K, Tokue Y. In vitro susceptibility of clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA) to manufactured generic drugs compared with the brand vancomycin. Int. J. Antimicrob. Agents31, 380–399 (2008).
   PubMed Web of Science ®Google Scholar
• Rodriguez CA, Agudelo M, Catano JC, Zuluaga AF, Vesga O. Potential therapeutic failure of generic vancomycin in a liver transplant patient with MRSA peritonitis and bacteremia. J. Infect.59, 277–280 (2009).
   PubMed Web of Science ®Google Scholar